Latest 20-F annual reports

QuantaSing Group Limited solidifies its operational structure in China through exclusive agreements while venturing into global markets with the acquisition of Kellys Education.

Mesoblast reports its FY24 results, highlighting efforts to secure regulatory approval for remestemcel-L and manage operational costs.

Iris Energy's annual 20-F filing provides a comprehensive overview of the company's financial performance, strategies, and risk factors for the fiscal year ended June 30, 2024.

NeuroMind AI Corp. files an amendment to its Form 20-F to correct a clerical error, incorporate financial statements, revise expert statements, and clarify its securities' trading market following its business combination.

Cloopen Group Holding Limited's Form 20-F filing details the company's financial performance and operational structure for the fiscal year ended December 31, 2022, highlighting key aspects of its business in the Chinese market.

Earlyworks Co., Ltd. files its annual report on Form 20-F, detailing its financial results for the fiscal year ended April 30, 2024, and outlining its business strategies and risk factors.

Ming Shing Group Holdings Limited's 20-F filing highlights its financial results, operational details, and future growth plans within the Hong Kong wet trades works industry.

Jianzhi Education Technology Group reports a decrease in revenue for the year ended December 31, 2023, as the company navigates a strategic shift in its business operations.

TROOPS, Inc. amends its annual report on Form 20-F to update Section 302 and 906 certifications.

Rezolve AI Limited completes a warrant agreement with Computershare Inc. to manage warrants previously issued by Armada Acquisition Corp. I, now exercisable for Rezolve AI ordinary shares.

Virax Biolabs Group Limited files its annual report on Form 20-F, detailing its financial performance for the fiscal year ended March 31, 2024, and outlining its strategic focus on T cell in-vitro diagnostics.

Silver North Resources Ltd. files an amendment to its 20-F annual report to address SEC staff comments regarding auditor's going concern language and compliance with Form 6-K filing requirements.

NewGenIvf Group Limited files its annual report on Form 20-F, including a code of conduct emphasizing ethical and legal compliance.

Skillful Craftsman Education Technology Limited files its Form 20-F, reporting financial results for the fiscal year ended March 31, 2024, highlighting challenges and strategic adjustments in a competitive market.

HUB Cyber Security Ltd. enters into a securities purchase agreement to issue convertible notes and warrants to accredited investors, aiming to raise capital for general corporate purposes.

C21 Investments Inc. files a transition report on Form 20-F/A to reflect its change in fiscal year-end from January 31 to March 31.

MKDWELL Tech Inc. finalizes its merger with Cetus Capital Acquisition Corp. and files a Form 20-F report detailing the transaction and related agreements.

Lytus Technologies Holdings PTV. Ltd. reports financial results for the year ended March 31, 2024, highlighting strategic initiatives, financial performance, and future outlook, while also amending an equity purchase agreement with Mast Hill Fund, L.P.

JBS S.A. files an amendment to its 20-F annual report to address comments received from the SEC, revising several sections including financial statements.

Visionary Holdings Inc. releases its Form 20-F, detailing financial performance for the fiscal year ending March 31, 2024, highlighting a shift towards high technology, life sciences, and AI education.

Polestar and Volvo Car Corporation have amended several agreements to enhance their collaboration in areas such as change management, spare parts supply, vehicle development, and manufacturing engineering.

LakeShore Biopharma details executive employment terms and compliance in recent SEC filings.

Portage Biotech initiates strategic review, including potential asset sales or merger, due to funding challenges and discontinuation of certain clinical trials.

Polestar secures agreements for manufacturing support, intellectual property licensing, and financial stability as it scales production and navigates industry complexities.

SuperCom Ltd. files an amendment to its 20-F annual report to include consolidated financial statements for 2021, an updated audit report, and revisions to operating and financial reviews.

Evotec SE's 2023 annual report reveals a 4% revenue increase but also highlights a net loss and strategic risks amidst global uncertainties.

OKYO Pharma's fiscal year 2024 results highlight advancements in their OK-101 clinical program for dry eye disease and neuropathic corneal pain, despite ongoing financial challenges.

China SXT Pharmaceuticals reports a decrease in revenue but a significant reduction in net loss for the fiscal year ended March 31, 2024, while navigating complex regulatory landscapes in China and the U.S.

ZK International reports its fiscal year 2023 results, highlighting financial losses, strategic shifts in investments, and ongoing efforts to maintain Nasdaq compliance.

Primega Group Holdings Limited files its annual report on Form 20-F, detailing its financial performance for the fiscal year ended March 31, 2024, and outlining various risk factors and operational strategies.